EuroInf: A Multicenter Comparative Observational Study of Apomorphine and Levodopa Infusion in Parkinson's Disease
暂无分享,去创建一个
P. Svenningsson | J. Volkmann | H. Reichmann | L. Timmermann | G. Ebersbach | K. Chaudhuri | P. Martínez-Martín | M. Samuel | P. Reddy | A. Antonini | R. Katzenschlager | K. Wenzel | Z. Pirtošek | A. Storch | M. Kramberger | M. Trost | S. Pålhagen | H. Dafsari | P. Odin | T. Henriksen | A. Rizos | Anne Martin | D. Calandrella | Arne Glad | A. Todorova | Narissah Bryndum | V. Tomantschger
[1] Houeto Jean-Luc. [Parkinson's disease]. , 2022, La Revue du praticien.
[2] W. Oertel,et al. Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.
[3] K. Kieburtz,et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study , 2014, The Lancet Neurology.
[4] G. Ebersbach,et al. Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery. , 2013, Parkinsonism & related disorders.
[5] K. Chinthapalli. NICE is dead; long live NICE , 2013, BMJ : British Medical Journal.
[6] C. Mariani,et al. Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome , 2013, Journal of Neurology, Neurosurgery & Psychiatry.
[7] S. Acaster,et al. Methods for interpreting change over time in patient-reported outcome measures , 2013, Quality of Life Research.
[8] G. Ebersbach,et al. Severe gastrointestinal complications in patients with levodopa/carbidopa intestinal gel infusion , 2012, Movement disorders : official journal of the Movement Disorder Society.
[9] I. Forgacs,et al. Intrajejunal Levodopa Versus Conventional Therapy in Parkinson Disease: Motor and Nonmotor Effects , 2012, Clinical neuropharmacology.
[10] F. Valldeoriola,et al. Polyneuropathy while on duodenal levodopa infusion in Parkinson’s disease patients: we must be alert , 2012, Journal of Neurology.
[11] C. Clarke,et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[12] P. Layer,et al. Subacute axonal neuropathy in Parkinson's disease with cobalamin and vitamin B6 deficiency under duodopa therapy , 2010, Movement disorders : official journal of the Movement Disorder Society.
[13] A. Lang,et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. , 2010, Archives of neurology.
[14] M Zappia,et al. International study on the psychometric attributes of the Non-Motor Symptoms Scale in Parkinson disease , 2009, Neurology.
[15] K. Chaudhuri,et al. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment , 2009, The Lancet Neurology.
[16] Paolo Barone,et al. The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study , 2007, Movement disorders : official journal of the Movement Disorder Society.
[17] K. Chaudhuri,et al. Non-motor symptoms of Parkinson's disease: diagnosis and management , 2006, The Lancet Neurology.
[18] R. Hays,et al. Clinical significance of patient-reported questionnaire data: another step toward consensus. , 2005, Journal of clinical epidemiology.
[19] W. Poewe,et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.
[20] G. Norman,et al. Interpretation of Changes in Health-related Quality of Life: The Remarkable Universality of Half a Standard Deviation , 2003, Medical care.
[21] R. Fitzpatrick,et al. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. , 1997, Age and ageing.
[22] P. Leigh,et al. Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment. , 1997, Parkinsonism & related disorders.
[23] D. Easter,et al. Radiologic, endoscopic, and surgical gastrostomy: an institutional evaluation and meta-analysis of the literature. , 1995, Radiology.
[24] Lewis E. Kazis,et al. Effect Sizes for Interpreting Changes in Health Status , 1989, Medical care.
[25] M. Hoehn,et al. Parkinsonism , 1967, Neurology.
[26] S. Factor,et al. Daytime REM sleep in Parkinson's disease. , 2013, Parkinsonism & related disorders.
[27] K. Chaudhuri,et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect. , 2011, Journal of Parkinson's disease.
[28] K. Chaudhuri,et al. The challenge of non-motor symptoms in Parkinson's disease. , 2010, Progress in brain research.
[29] A. Bonnet,et al. [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.
[30] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[31] R A Deyo,et al. Assessing the responsiveness of functional scales to clinical change: an analogy to diagnostic test performance. , 1986, Journal of chronic diseases.